Ascendis Pharma (ASND)
Ascendis Pharma on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
3.5M
Short interest
settlement 2026-09-30
3.7
Days to cover
-1.2 days vs prior
52.0%
Short share of volume
2026-10-09
974
Fails to deliver
settlement 2026-09-02
-$380K
Insider flow, 90 days
2 buys, 2 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in ASND is 3,484,067 shares, down 719,154 shares over the last month. Over the last 48 readings it ranged from 1,720,143 shares (29 May 2026) to 4,384,256 shares (14 March 2025). At the reported average volume of 937K shares a day that is 3.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/asnd" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 3,484,067 | -12.1% | 937,174 | 3.72 |
| 2026-09-15 | 3,961,960 | -5.7% | 808,088 | 4.90 |
| 2026-08-31 | 4,203,221 | +14.0% | 442,630 | 9.50 |
| 2026-08-14 | 3,687,311 | +8.3% | 589,552 | 6.25 |
| 2026-07-31 | 3,404,687 | +9.7% | 472,453 | 7.21 |
| 2026-07-15 | 3,104,151 | -5.3% | 552,854 | 5.61 |
| 2026-06-30 | 3,277,898 | +65.0% | 1,302,350 | 2.52 |
| 2026-06-15 | 1,987,044 | +15.5% | 576,428 | 3.45 |
| 2026-05-29 | 1,720,143 | -0.1% | 555,522 | 3.10 |
| 2026-05-15 | 1,721,179 | -39.2% | 623,378 | 2.76 |
| 2026-04-30 | 2,832,689 | -22.5% | 929,764 | 3.05 |
| 2026-04-15 | 3,654,940 | -1.1% | 658,910 | 5.55 |
| 2026-03-31 | 3,695,502 | -4.0% | 390,907 | 9.45 |
| 2026-03-13 | 3,850,275 | -0.6% | 766,816 | 5.02 |
| 2026-02-27 | 3,871,638 | +1.8% | 638,079 | 6.07 |
| 2026-02-13 | 3,802,853 | +31.3% | 848,679 | 4.48 |
| 2026-01-30 | 2,896,919 | -8.4% | 698,310 | 4.15 |
| 2026-01-15 | 3,162,754 | -8.4% | 655,993 | 4.82 |
| 2025-12-31 | 3,453,178 | +1.9% | 581,521 | 5.94 |
| 2025-12-15 | 3,388,247 | +2.8% | 848,261 | 3.99 |
| 2025-11-28 | 3,296,433 | +10.3% | 534,264 | 6.17 |
| 2025-11-14 | 2,987,645 | -15.8% | 629,597 | 4.75 |
| 2025-10-31 | 3,549,505 | +3.7% | 389,923 | 9.10 |
| 2025-10-15 | 3,422,190 | +33.5% | 468,473 | 7.30 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of ASND volume is 52.0%, up 9.8 points over the last five sessions. Over the last 30 readings it ranged from 35.4% (21 September 2026) to 78.4% (6 October 2026). The latest reading is 7.9 points below the 30-session average of 60.0%, on 383K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 199K | 383K | 52.0% | 0 |
| 2026-10-08 | 258K | 350K | 73.7% | 2 |
| 2026-10-07 | 169K | 334K | 50.6% | 0 |
| 2026-10-06 | 408K | 520K | 78.4% | 10,498 |
| 2026-10-05 | 180K | 273K | 65.9% | 18 |
| 2026-10-02 | 130K | 307K | 42.2% | 10 |
| 2026-10-01 | 179K | 350K | 51.2% | 0 |
| 2026-09-30 | 173K | 481K | 36.0% | 0 |
| 2026-09-29 | 139K | 215K | 64.6% | 0 |
| 2026-09-28 | 229K | 302K | 75.8% | 0 |
| 2026-09-25 | 142K | 243K | 58.4% | 108 |
| 2026-09-24 | 363K | 626K | 58.0% | 0 |
| 2026-09-23 | 336K | 544K | 61.7% | 7 |
| 2026-09-22 | 109K | 287K | 38.0% | 0 |
| 2026-09-21 | 183K | 517K | 35.4% | 24,907 |
| 2026-09-18 | 244K | 446K | 54.6% | 0 |
| 2026-09-17 | 296K | 510K | 58.0% | 52 |
| 2026-09-16 | 273K | 456K | 59.8% | 5,212 |
| 2026-09-15 | 884K | 1.4M | 63.1% | 10,917 |
| 2026-09-14 | 119K | 177K | 67.1% | 0 |
| 2026-09-11 | 136K | 186K | 72.9% | 0 |
| 2026-09-10 | 145K | 189K | 76.5% | 0 |
| 2026-09-09 | 182K | 243K | 74.9% | 0 |
| 2026-09-08 | 116K | 219K | 53.0% | 0 |
| 2026-09-04 | 240K | 403K | 59.5% | 0 |
| 2026-09-03 | 268K | 460K | 58.3% | 80 |
| 2026-09-02 | 150K | 221K | 67.7% | 0 |
| 2026-09-01 | 166K | 273K | 60.9% | 0 |
| 2026-08-31 | 294K | 467K | 63.1% | 20 |
| 2026-08-28 | 93K | 137K | 67.6% | 1,493 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 2 September 2026, the fails-to-deliver balance in ASND is 974 shares, up 673 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (12 August 2026) to 34,042 shares (28 April 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-02 | 974 | $260.25 | $253K |
| 2026-08-24 | 301 | $253.29 | $76K |
| 2026-08-12 | 3 | $254.57 | $764 |
| 2026-07-20 | 61 | $261.00 | $16K |
| 2026-07-16 | 591 | $268.57 | $159K |
| 2026-07-14 | 10,013 | $265.22 | $2.7M |
| 2026-07-13 | 2,878 | $270.45 | $778K |
| 2026-07-10 | 2,605 | $275.43 | $717K |
| 2026-07-08 | 15,001 | $266.97 | $4.0M |
| 2026-06-30 | 1,058 | $263.70 | $279K |
| 2026-06-29 | 14,102 | $260.75 | $3.7M |
| 2026-06-18 | 352 | $231.15 | $81K |
| 2026-06-15 | 519 | $218.06 | $113K |
| 2026-06-12 | 79 | $215.60 | $17K |
| 2026-05-26 | 10 | $247.05 | $2K |
| 2026-05-22 | 1,457 | $247.51 | $361K |
| 2026-05-21 | 2,173 | $241.34 | $524K |
| 2026-05-18 | 12,587 | $240.50 | $3.0M |
| 2026-05-15 | 1,549 | $245.49 | $380K |
| 2026-05-13 | 9,023 | $237.65 | $2.1M |
| 2026-05-08 | 174 | $246.14 | $43K |
| 2026-05-07 | 181 | $235.90 | $43K |
| 2026-05-06 | 16,215 | $225.28 | $3.7M |
| 2026-05-05 | 16,175 | $228.71 | $3.7M |
| 2026-05-04 | 14,338 | $220.93 | $3.2M |
| 2026-05-01 | 3,615 | $229.38 | $829K |
| 2026-04-30 | 5,558 | $220.28 | $1.2M |
| 2026-04-29 | 213 | $222.08 | $47K |
| 2026-04-28 | 34,042 | $226.66 | $7.7M |
| 2026-04-27 | 9 | $229.27 | $2K |
Insider trades
SEC Form 4, newest first. JSONOver the last 90 days ASND insiders reported 2 open-market buys ($493K) against 2 sells ($873K), so the dollar flow leans toward selling. Latest filing: Bodenhoff Mads (SVP & PAO) on 2026-09-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Bodenhoff Mads | SVP & PAO | Sell | 3K | $270.19 | $811K | 0 |
| 2026-09-08 | Bodenhoff Mads | SVP & PAO | Option exercise | 3K | $110.00 | $330K | 3K |
| 2026-09-02 | HOLTUG LARS | Director | Sell | 236 | $264.13 | $62K | 4K |
| 2026-08-14 | BIENAIME JEAN JACQUES | Director | Buy | 900 | $246.91 | $222K | 3K |
| 2026-08-14 | BIENAIME JEAN JACQUES | Director | Buy | 1K | $245.85 | $270K | 2K |
| 2026-06-02 | SMITH SCOTT THOMAS | EVP & Chief Financial Officer | Buy | 100 | $219.00 | $22K | 4K |
| 2026-05-29 | BIENAIME JEAN JACQUES | Director | Buy | 200 | $222.30 | $44K | 800 |
| 2026-05-29 | BIENAIME JEAN JACQUES | Director | Buy | 100 | $223.50 | $22K | 900 |
| 2026-05-29 | BIENAIME JEAN JACQUES | Director | Buy | 200 | $223.76 | $45K | 600 |
| 2026-05-29 | SMITH SCOTT THOMAS | EVP & Chief Financial Officer | Buy | 250 | $223.32 | $56K | 4K |
| 2026-05-26 | BIENAIME JEAN JACQUES | Director | Buy | 200 | $239.37 | $48K | 400 |
| 2026-05-26 | BIENAIME JEAN JACQUES | Director | Buy | 200 | $236.24 | $47K | 200 |
| 2026-05-11 | JENSEN FLEMMING STEEN | See Remarks | Sell | 19K | $238.49 | $4.6M | 0 |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON28 Form 144 notices on file for ASND worth $108.3M at the prices reported; 2 in the last 90 days worth $873K. Latest: Bodenhoff Mads filed on 2026-09-08 to sell 3,000 shares ($811K) from 2026-09-08.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-08 | Bodenhoff MadsOfficer | 3K | $811K | 0.005% | 2026-09-08 | Merrill Lynch |
| 2026-09-02 | HOLTUG LARSDirector | 236 | $62K | 0.000% | 2026-09-02 | CITIGROUP GLOBAL MARKETS |
| 2026-05-11 | JENSEN FLEMMING STEENOfficer, EXECUTIVE VP HEAD OF PRODUCT SUPPLY AND QUALITY | 19K | $4.6M | 0.031% | 2026-05-11 | CITIGROUP GLOBAL MARKETS |
| 2026-03-09 | SINGEL STINAOfficer | 4K | $908K | 0.006% | 2026-03-09 | Merrill Lynch |
| 2026-03-06 | SMITH SCOTT THOMASOfficer | 10K | $2.4M | 0.016% | 2026-03-05 | Merrill Lynch |
| 2026-03-06 | Bodenhoff MadsOfficer | 10K | $2.4M | 0.016% | 2026-03-06 | Merrill Lynch |
| 2026-03-05 | Jan Moller MikkelsenCEO, Officer | 94K | $22.7M | 0.152% | 2026-03-05 | J.P. Morgan Securities LLC |
| 2026-03-05 | Shu AimeeOfficer | 6K | $1.3M | 0.009% | 2026-03-05 | Merrill Lynch |
| 2026-03-05 | SMITH SCOTT THOMASOfficer | 10K | $2.4M | 0.016% | 2026-03-05 | Merrill Lynch |
| 2026-03-04 | Shu AimeeOfficer, EXECUTIVE VICE PRESIDENT CHIEF MEDICAL OFFICER | 7K | $1.7M | 0.012% | 2026-03-04 | CITIGROUP GLOBAL MARKETS |
| 2026-03-04 | Morrison LisaOfficer | 10K | $2.4M | 0.016% | 2026-03-04 | Merrill Lynch |
| 2026-03-02 | Fairey WilliamDirector | 2K | $436K | 0.003% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-03-02 | IMANI SIHAMDirector | 2K | $436K | 0.003% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-03-02 | SMITH SCOTT THOMASOfficer, EXECUTIVE VP CHIEF FINANCIAL OFFICER | 18K | $4.4M | 0.030% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-03-02 | JENSEN MICHAEL WOLFFOfficer, EXECUTUVE VP CHIEF LEGAL OFFICER | 18K | $4.4M | 0.030% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-03-02 | Bodenhoff MadsOfficer, SENIOR VP PRINCIPAL ACCOUNTING OFFICER | 7K | $1.7M | 0.011% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-03-02 | PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERGOfficer, EXECUTIVE VP CHIEF ADMINISTRATIVE OFFICER | 11K | $2.6M | 0.017% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-03-02 | Morrison LisaDirector | 2K | $508K | 0.003% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-03-02 | HOLTUG LARSDirector | 2K | $508K | 0.003% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-03-02 | SPROGOE KENNETTOfficer, EXECUTIVE VP HEAD OF RESEARCH AND PROD DEVELOPMENT | 11K | $2.6M | 0.017% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-03-02 | JENSEN FLEMMING STEENOfficer, EXECUTIVE VP HEAD OF PRODUCT SUPPLY AND QUALITY | 11K | $2.6M | 0.017% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-03-02 | Cha AlbertDirector | 2K | $508K | 0.003% | 2026-03-02 | CITIGROUP GLOBAL MARKETS |
| 2026-01-13 | MIKKELSEN JAN MOLLEROfficer, PRESIDENT CEO | 87K | $18.4M | 0.141% | 2026-01-13 | CITIGROUP GLOBAL MARKETS |
| 2025-12-04 | JENSEN MICHAEL WOLFFOfficer | 10K | $2.1M | 0.016% | 2025-12-04 | Merrill Lynch |
| 2025-12-02 | Jan Moller MikkelsenCEO, Officer | 100K | $21.1M | 0.165% | 2025-12-02 | J.P. Morgan Securities LLC |
| 2025-12-02 | SPROGOE KENNETTOfficer | 10K | $2.1M | 0.016% | 2025-12-02 | Merrill Lynch |
| 2025-12-02 | JENSEN FLEMMING STEENOfficer | 10K | $2.1M | 0.016% | 2025-12-02 | Merrill Lynch |
| 2025-12-01 | SINGEL STINAOfficer | 218 | $46K | 0.000% | 2025-12-01 | Merrill Lynch |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of ASND in their latest filing, all on Schedule 13G (passive). The largest reported stake is T. Rowe Price Investment Management, Inc. at 10.5% of the class (6,506,219 shares), filed 2026-05-07 for an event on 2026-04-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-13 | 13G/Ano. 7 | Artisan Partners Asset Management Inc.parent holding company | 2.6M | 4.2% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 7 | Artisan Partners Holdings LPparent holding company | 2.6M | 4.2% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 7 | Artisan Investments GP LLCparent holding company | 2.6M | 4.2% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 7 | Artisan Partners Limited Partnershipinvestment adviser | 2.6M | 4.2% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 9 | JANUS HENDERSON GROUP PLCparent holding company | 3.7M | 6.0% | 2026-03-31 |
| 2026-05-14 | 13G/Ano. 1 | Capital International Investorsinvestment adviser | 2.0M | 3.2% | 2026-03-31 |
| 2026-05-07 | 13G/Ano. 1 | T. Rowe Price Investment Management, Inc.investment adviser | 6.5M | 10.5% | 2026-04-30 |
| 2026-05-06 | 13G/Ano. 12 | FMR LLCparent holding company | 3.9M | 6.6% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 12 | Abigail P. Johnsonindividual | 3.9M | 6.6% | 2026-03-31 |
| 2026-02-11 | 13G/Ano. 4 | Westfield Capital Management Company, L.P.investment adviser | 5.2M | 8.5% | 2025-12-31 |
13F holders
Tracked managers holding ASND at their latest 13F. JSON5 of the 30 tracked managers held ASND at their latest 13F, $229.6M in total at quarter-end prices. Two Sigma Investments is the largest at $81.6M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 306K | $81.6M | 0.06% | new |
| Millennium Management | 2026-06-30 | 267K | $71.1M | 0.03% | new |
| Citadel Advisors | 2026-06-30 | 138K | $36.8M | 0.00% | new |
| Renaissance Technologies | 2026-06-30 | 120K | $31.9M | 0.04% | new |
| D. E. Shaw & Co. | 2026-06-30 | 31K | $8.2M | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Ascendis Pharma in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Ascendis Pharma (ASND), SEC CIK 1612042, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-02.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-08.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1612042Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUnited Therapeutics
- CPIXCumberland Pharmaceuticals
- REGNRegeneron Pharmaceuticals
- LLYEli Lilly
- VRTXVertex Pharmaceuticals
- ALNYAlnylam Pharmaceuticals
- CYTKCytokinetics
- BMYBristol Myers Squibb
- PTCTPTC Therapeutics
- INSMInsmed
- MDGLMadrigal Pharmaceuticals
- CORTCorcept Therapeutics
- IONSIonis Pharmaceuticals
- SDGRSchrodinger
- ROIVRoivant Sciences
- JNJJohnson & Johnson
- OPKOpko Health
- ALKSAlkermes
- ABBVAbbVie
- ABTAbbott Laboratories
- KNSAKiniksa Pharmaceuticals International
- BBIOBridgeBio Pharma
- ZTSZoetis
- JAZZJazz Pharmaceuticals
Datasets
Frequently Asked Questions
How much of ASND is sold short?
What is ASND's daily short volume?
Does ASND have fails to deliver?
Are ASND insiders buying or selling?
Have ASND insiders filed to sell?
Who owns 5% or more of ASND?
Which tracked 13F managers own ASND?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.